Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14180287 | 0.74 | CYP2C19 (0.33) | CCR2 | |
| SCHEMBL7177396 | 0.72 | TACR2 (0.36) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1446220 | 0.71 | SLC6A3 (0.51) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL7772327 | 0.70 | LMNA (0.37) | SLC6A3SLC6A2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24111955 | 0.69 | CYP2A6 (0.33) | — | |
| SCHEMBL28048051 | 0.69 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3066773 | 0.66 | HDAC4 (0.37) | — | |
| SCHEMBL9225480 | 0.65 | SLC6A3 (0.46) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL9230201 | 0.65 | SLC6A3 (0.40) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23231379 | 0.65 | SLC6A3 (0.46) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378521-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7223860-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-7038044-B1 | Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-05-02 | — | — | US | disclosed |
| EP-1200417-B1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | disclosed |
| EP-1200417-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001004105-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | ADH1C, ADH1A, ADH5 | SLC6A3 384/4885SLC6A2 427/4885CHRNA1 255/4885 |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | ADH1C, ADH1A, ADH5 | SLC6A3 384/4885SLC6A2 427/4885CHRNA1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.